[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337384-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337384-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-value-of-cyclin-b1-and-cyclin-b2-expression-in-breast-cancer-a-systematic-review-and-updated-meta-analysis","Prognostic value of cyclin B1 and cyclin B2 expression in breast cancer - A systematic review and updated meta-analysis","","Cyclin B1 and cyclin B2 regulate cell-cycle progression and have been studied as prognostic biomarkers across cancers. This systematic review and updated meta-analysis assesses how cyclin B1/B2 expression relates to outcomes in breast cancer, using survival data and clinicopathological parameters. PubMed, Embase, MEDLINE, Web of Science, and Cochrane were searched, hazard ratios and odds ratios were pooled, heterogeneity was examined, and publication bias was evaluated.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-value-of-cyclin-b1-and-cyclin-b2-expression-in-breast-cancer-a-systematic-review-and-updated-meta-analysis/337384/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-value-of-cyclin-b1-and-cyclin-b2-expression-in-breast-cancer-a-systematic-review-and-updated-meta-analysis/337384.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this systematic review and updated meta-analysis?","Question",{"text":63,"@type":64},"To evaluate the prognostic value of cyclin B1 and cyclin B2 expression in breast cancer using pooled survival and clinicopathological data from multiple studies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which databases were searched, and how was the literature search performed?",{"text":68,"@type":64},"The authors searched PubMed, Embase, MEDLINE, Web of Science, and Cochrane library using keyword combinations involving cyclin B1/CCNB1 and cyclin B2/CCNB2 together with breast cancer, plus manual searching from reference lists.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes are reported as significantly associated with high cyclin B1 or cyclin B2 expression?",{"text":72,"@type":64},"High cyclin B1 expression was linked to worse overall survival, disease-specific survival, and disease-free survival. High cyclin B2 expression was associated with worse disease-specific survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337384,1790046531,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","®  \nSystematic Review and Meta-Analysis   \nPrognostic value of cyclin B1 and cyclin B2 expression in breast cancer  \nA systematic review and updated meta-analysis  \nJeongwan Kang, MDa , Hera Jung, MDa , Hyunchul Kim, MDa ,*  \n\n| Abstract\u003Cbr>Background: Cyclin B1 and cyclin B2 are key regulators of cell cycle progression and have been implicated in the prognostic significance of various cancers. This meta-analysis aimed to evaluate the prognostic value of cyclin B1 and B2 expression in breast cancer.\u003Cbr>Methods: A comprehensive literature search was conducted on Pubmed, Embase, MEDLINE, Web of Science, and Cochrane library. Studies with survival data and clinicopathological parameters associated with cyclin B1 and B2 or CCNB1 and CCNB2 genes were included. Survival data and clinicopathological parameters associated with cyclin B1 and B2 expression were extracted. Pooled hazard ratios and odds ratios with 95% confidence intervals were calculated. Subgroup analysis was conducted to assess heterogeneity. Publication bias was evaluated.\u003Cbr>Results: A total of 23 studies were included in the analysis. High expression of cyclin B1 was significantly associated with worse overall survival (hazard ratio [HR] = 1.69, P \u003C .01), disease-specific survival (HR = 1.71, P \u003C .01), and disease-free survival (HR = 2.01, P = .01) . High expression of cyclin B2 was associated with worse disease-specific survival (HR = 2.46, P = .02) . Clinicopathological parameters did not show significant associations with cyclin B1 and B2 expressions. When data on cyclin B1 and B2 were combined, a significant age-related difference was found (odds ratio = 0.62, P = .04) .\u003Cbr>Conclusions: This meta-analysis provides evidence supporting the prognostic significance of cyclin B1 and B2 expression in breast cancer. High expression of cyclin B1 and B2 is associated with worse survival, indicating their potential as prognostic markers in breast cancer.\u003Cbr>Abbreviations: DFS = disease free survival, DSS = disease specific survival, HR = hazard ratio, NOS = Newcastle-Ottawa scale, OR = odds ratio, OS = overall survival. |\n| --- |\n| Keywords: biomarker, breast cancer, cyclin B1 , cyclin B2 , prognosis |\n\n1. Introduction  \nBreast cancer is the most prevalent female cancer in the United States with approximately 280,000 new cases and over 40,000 deaths a year.[1] Continuous efforts are being made to develop new treatment methods to improve the survival rates of breast cancer patients.[2] Biomarkers are being studied for prognostic and predictive applications in breast cancer patients.[3]  \nCyclin B1, and B2 proteins, along with their coding genes CCNB1, and CCNB2 are among such prognostic biomarkers for breast cancer.[4] Cyclin B1 and B2 are members of the cyclin family and play important roles in controlling the cell cycle by interacting with other cell cycle-regulating molecules.[5,6] They form complexes with CDK1 to promote mitosis, particularly  \nThe authors have no funding and conflicts of interest to disclose. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.  \nThis study is a meta-analysis that does not involve ethical norms and there is no need for ethical approval.  \naDepartment of Pathology, CHA Ilsan Medical Center, Goyang-si, Gyeonggi-do, Republic of Korea.  \n* Correspondence: Hyunchul Kim, Department of Pathology, CHA Ilsan Medical Center, 1205 Jungang-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10414, Republic of Korea ([e-mail: hyunchulk@chamc.co.kr](e-mail: hyunchulk@chamc.co.kr)).  \nplaying significant roles in G2/M transition. [7,8] The expression of cyclin B1 and B2 has been associated with the prognosis and clinicopathological parameters of breast cancer.[4] However, conflicting results have been reported in different studies. [9–19] A meta-analysis conducted in 2017 found significant associations between high expression of cyclin B1 and B2 proteins and worse prognosis an","cbCail7XbMGC4Pzt","https://ap.wps.com/l/cbCail7XbMGC4Pzt","pdf",1316405,"English","# Abstract\n# Introduction\n# Methods\n## Study design and literature search\n## Literature selection","[{\"question\":\"What is the main purpose of this systematic review and updated meta-analysis?\",\"answer\":\"To evaluate the prognostic value of cyclin B1 and cyclin B2 expression in breast cancer using pooled survival and clinicopathological data from multiple studies.\"},{\"question\":\"Which databases were searched, and how was the literature search performed?\",\"answer\":\"The authors searched PubMed, Embase, MEDLINE, Web of Science, and Cochrane library using keyword combinations involving cyclin B1/CCNB1 and cyclin B2/CCNB2 together with breast cancer, plus manual searching from reference lists.\"},{\"question\":\"What outcomes are reported as significantly associated with high cyclin B1 or cyclin B2 expression?\",\"answer\":\"High cyclin B1 expression was linked to worse overall survival, disease-specific survival, and disease-free survival. High cyclin B2 expression was associated with worse disease-specific survival.\"}]","Prognostic value of cyclin B1 and cyclin B2 expression in breast cancer - A systematic review and updated meta-analysis | PDF",1790018929,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/967e7c1b66154a6525d5a1eb57fe56e3.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78b34284451fb1945b8fe4579a9d336b.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c80936b883b02916c66503a1bce52a2a.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f77041789cfe7b50bfa947a16609db9.webp",980,1306]